At Trevena, our mission is to deliver innovative medicines to patients and healthcare providers confronting serious medical conditions.

Oliceridine injection, our lead product candidate, is a G protein-selective agonist at the mu‑opioid receptor being developed for the management of moderate to severe acute pain in hospitals or other controlled clinical settings where intravenous, or IV, opioid therapy is warranted.

We are dedicated to discovering and developing therapies intended to provide valuable improvements to patient care.

Our pipeline includes several additional product candidates we have identified as potential best- or first-in-class therapies for a variety of critical unmet medical needs. These are all new molecules discovered by Trevena scientists using our proprietary platform.